Palvella Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2025	FY 2024	FY 2023	FY 2023
Period Ending	Apr '26 Apr 9, 2026	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jun '23 Jun 30, 2023
Market Cap	1,877	1,296	249	132	-	-
Market Cap Growth	500.17%	419.85%	88.64%	-	-	-
Enterprise Value	1,853	1,238	249.28	48.54	0	0
Last Close Price	131.13	104.67	22.54	12.00	-	-
PE Ratio	-	-28.21	-6.08	-1.53	-	-
PB Ratio	54.50	46.31	-	2.11	-	-
P/TBV Ratio	52.60	42.09	-	0.43	-	-
P/FCF Ratio	-	-51.82	-9.97	-12.19	-	-
P/OCF Ratio	-	-51.82	-9.97	-12.19	-	-
EV/EBITDA Ratio	-	-32.08	-6.46	-3.44	-	-
EV/EBIT Ratio	-	-32.08	-6.46	-3.44	-	-
EV/FCF Ratio	-	-49.52	-9.97	-4.48	-	-
Debt / Equity Ratio	0.02	0.02	-	0	0	-
Debt / EBITDA Ratio	-0.02	-0.02	-	-	-	-
Debt / FCF Ratio	-0.02	-0.02	-	-	-	-
Net Debt / Equity Ratio	-2.05	-2.05	-	-1.33	0.10	-
Net Debt / EBITDA Ratio	1.49	1.49	-	5.93	0.62	-
Net Debt / FCF Ratio	2.29	2.29	-	7.71	0.54	-
Quick Ratio	5.11	5.11	-	7.14	3.11	-
Current Ratio	5.20	5.20	-	7.33	3.20	-
Return on Equity (ROE)	-92.10%	-92.10%	-133.26%	293.60%	-80.30%	-175.75%
Return on Assets (ROA)	-52.24%	-52.24%	-87.50%	-29.43%	-23.04%	-122.85%
Return on Invested Capital (ROIC)	603.30%	603.30%	1422.33%	371.41%	-123.26%	-547.63%
Return on Capital Employed (ROCE)	-62.06%	-62.06%	-101.32%	-34.64%	-37.04%	-199.14%
Earnings Yield	-2.20%	-3.54%	-16.46%	-65.25%	-	-
FCF Yield	-	-1.93%	-10.03%	-8.20%	-	-
Buyback Yield / Dilution	-405.46%	-1.88%	-396.13%	-24.08%	-64.84%	80.97%
Total Shareholder Return	-405.46%	-1.88%	-396.13%	-24.08%	-64.84%	80.97%

Updated Mar 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q